CONSENT TO PARTICIPATE IN RESEARCH
The University of Mississippi Medical Center
Study Title:  A Mobile Intervention to Improve Uptake of PrEP for  
Southern Black MSM: Randomized Controlled  
Phase
Principal Investigator(s):  
Mississippi – Leandro Mena M.D., M.P.H. 
   University of Mississippi Medical Center
  Jackson, MS
Rhode Island – Laura Whiteley, M.D.
       Brown University 
       Providence, RI
Site(s): Open Arms Healthcare Center
_____________________________________________________
Introduction      
You are being invited to take part in this research project because you are a male age  
18-35 years (assigned male at birth) who is not currently taking pre-exposure  
prophylactic (PrEP) medication to prevent HIV
Purpose     
The purpose of this study is to evaluate if a mobile messaging intervention improves  
HIV-related knowledge and attitudes and attendance at PrEP appointments.
Procedures
If you agree to participate in this study, you will have three appointments over 4 months.
During your first appointment , you will complete a questionnaire regarding demographic  
information, sexual and drug behaviors, adherence to medical treatment, and HIV  
knowledge and attitudes. You may choose not to answer any questions that make you  
uncomfortable. 
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021
Also during your first study appointment, y ou will be assigned, by chance, to participate  
in one of the following two study groups:
(1) Group One: You will receive text with intervention content and follow-up  
questions over the next 4 weeks, on your cell phone. You will receive approximately  
8-16 text messages with links to web content and questions about PrEP and HIV  
Transmission, HIV prevention, and correcting misconceptions about HIV and PrEP.  
Texts will be sent twice a week over the next 4 weeks. 
OR
(2) Group Two:  You will be given feedback regarding your PrEP eligibility, current  
risk behavior, and future plans. You will also be given an informational handout about  
PrEP, shown a brief video, and given contact information for the Clinic Care  
Coordinator. 
All participants will have follow-up appointments at 5 weeks and 17 weeks with a  
member of the research team at Open Arms Healthcare Center. Study personnel will  
contact you to confirm your research appointments prior to the scheduled week 5  
and week 17 dates. During these appointments we will ask you to complete a  
questionnaire about your demographic information, sexual and drug behaviors, how  
you manage your medication(s), and HIV knowledge and attitudes. We will also  
review your medical record at Open Arms Healthcare Center and collect information  
related to the PrEP care that you may receive during your participation in the study. 
Length of Participation
Your participation in this study will last about 4 months.
Risks
Y ou may experience some psychological distress or emotional discomfort while 
answering some of the questions asked on the questionnaires regarding 
sexuality, PrEP, and medical care or viewing some of the mobile content about  
those topics. You may choose to stop completing the questionnaire   at any time 
and do not have to answer any questions that make you feel uncomfortable.
Although every effort will be made to keep your information confidential, there is 
the risk of breach of confidentiality. A breach of confidentiality could occur if 
information about your identity is given to a third party. To protect your identity, 
we will keep personal information about you private.
Benefits  
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021
You will not receive a direct benefit from being in this research study. We hope to learn  
information that may help others in the future.  The information we gain may be used to  
improve the effectiveness of interventions to improve knowledge and engagement in  
PrEP-related care.
Alternatives
You do not have to be enrolled in this study to receive treatment or information about  
HIV or PrEP. If you choose not to participate in this study, information about PrEP and  
HIV risk prevention can be provided to you through the health educators at Open Arms  
Healthcare Center 
Costs
There will not be any additional costs to you if you participate in this study.
Research-related injury
In the case of injury or illness resulting from your participation in this study, medical  
treatment is available to you at the University of Mississippi Medical Center.  You will be  
charged the usual and customary charges for any such treatment you receive.
Compensation
You will receive:
•$50 for completing the first visit. 
•$40 for completing each follow-up visit (5 and 17 weeks)
•$10 for confirming your research appointment and contact  
information (prior to week 5’s visit), and
•$10 for confirming your research appointment and contact  
information (prior to week 17’s visit) 
Voluntary Participation     
Your participation in this study is voluntary.  If at any point you decide to discontinue  
participation in this study, you will not suffer a penalty or loss of benefits to which you  
are otherwise entitled. 
Withdrawal
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021
You may choose to stop your participat ion in this study at any time . If you decide 
to withdraw the information already collected about you may still be used in this  
study but additional information will not be collected.  Your decision to stop your  
participation will have no effect on the quality of medical care you receive at the  
University of Mississippi Medical Center . Your participation in this study can be 
stopped at any time by the study doctor without your consent due to not  
complying with study procedures or if you become HIV positive.
New Information
You will be told of any new information we learn during your participation in this  
study that may affect your willingness to participate. 
Confidentiality
Every effort will be made to keep the information we learn about you private. 
Study personnel, the study sponsor, (Lifespan, National Institute of Child Health 
and Human Development and  the National Institutes of Health), the Food and 
Drug Administration (FDA),  the Office for Human Research Protections (OHRP) 
and the University of Mississippi Medical Center’s Office of Grants and 
Contracts, Institutional Review Board (IRB) and Office of Integrity and 
Compliance may review the study records.
Protected Health Information
Protected health information is any personal health information through which 
you can be identified. The information collected in this study includes: your 
name, address, ZIP code, phone number, health insurance, education  level, 
information related to risk behaviors, medical record number,  clinical history, and 
lab results. A decision to participate in this research means that you agree to the 
use of your health information for the study described in this form. This 
information will not be released beyond the purposes of conducting this study. 
The information collected for this study will be kept indefinitely. While this study is  
ongoing you may not have access to research information, but you may request it  
after the research is completed. 
If the study results are published your name or other information that could 
identify you will not     be released beyond the purposes of conducting this study.
Your medical information and records, once disclosed, may be re-
disclosed and may no longer be protected by the Privacy Standards of 
the Health Insurance. Portability and Accountability Act (HIPAA), which is 
a federal regulation designed to protect medical information, including 
medical information and records created through research.
You have the right to cancel this authorization at any time by providing the 
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021
study doctor with a written request to cancel the authorization at the 
following address: Dr. Leandro Mena, University of Mississippi Medical 
Center, 2500 North State Street, Jackson, MS 39216 or you may call (601)  
984-5560 (answering service will take calls after hours and on weekends).  
If you cancel this authorization, medical information and records about you 
that were created before the authorization was cancelled will still be used 
and disclosed as needed to preserve the integrity of the study.
If you do not sign this consent document, you will not be allowed to 
participate in this study.
Number of Participants
We expect 70 participants to enroll in this study.
Questions
If you have questions about this study or need to report any problems, side effects, or  
injuries, please call Dr. Leandro Mena at 601-984-5560 (the answering service will take  
calls after hours and on weekends).  
You may discuss your rights as a research participant with the Chairman of the  
University of Mississippi Medical Center’s Institutional Review Board, 2500 North State  
Street, Jackson, Mississippi  39216; telephone, 601 984-2815; facsimile, 601 984-2961.  
The Institutional Review Board is a group of people not involved with this study who  
have reviewed the study to protect your rights. 
You will be given a copy of this consent document to keep for your records after it has  
been signed.
Statement of Participation
I have been told about this study and the possible risks and benefits.  My participation is  
voluntary and I may withdraw at any time without any penalty or loss of benefits to  
which I am entitled, including medical care at the University of Mississippi Medical  
Center.
By signing this form I am not giving up any legal I may have.  
________________________________
Participant’s Printed Name
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021
________________________________
Participant’s Signature
____________________________
Date
__________________________________________
Printed Name of Person Obtaining Consent
__________________________________________
Signature of Person Obtaining Consent
________________________________
Date
I acknowledge that the participant identified above has been entered into this study, with  
properly obtained informed consent.
________________________________
Signature of Investigator 
________________________________
Date
University of Mississippi Medical Center
FWA00003630
Protocol: 2017-0169
Approved: 05/05/2020
Expires: 05/04/2021